Included in the formulation
Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):VED
ONLS
АТХ:G.04.C.B.01 Finasteride
Pharmacodynamics:Irreversible competitive inhibition of testosterone-5α-pType II reductase) in the prostate gland and male external genital organs and testosterone-5α-pioductase type I (less) - in the hair follicles (a violation of the restoration of testosterone to a more active dihydrotestosteronehe).
Pharmacokinetics:Quickly and almost completely (80% bioavailability) is absorbed from the digestive tract. The maximum concentration is achieved after 1-2 hours. Binding to plasma proteins is 90%.It is excreted as metabolites by the kidneys (39%) and through the intestine (57%), the half-life is 6-8 hours.
Long-term (3-7 months) reception at a dose of 5 mg per day reduces the concentration of 5-alpha-dihydrotestosterone in serum by 70%. Reduces the volume of the gland, normalizes the altered urodynamics: increases the maximum urinary flow rate and the degree of patency of the urinary tract. In 50% of patients, clinical symptoms disappear after 12 months.
Indications:BenignI prostate hyperplasia (to reduce the size of the prostate gland, increase the maximum rate of urine outflow and reduce symptoms associated with hyperplasia, reduce the risk of acute urinary retention and the associated likelihood of surgery).
XIV.N40-N51.N40 Hyperplasia of the prostate
XVIII.R30-R39.R39.1 Other difficulties associated with urination
Contraindications:Hypersensitivityobstruction of the urinary tract, malignant prostate cancer, pregnancy and women of childbearing age, children under 18; lactose intolerance, lactase deficiency, glucose-galactose(due to the presence of monohydrate in the lactose).
Carefully:Violation of liver function, obstructive uropathy.
Pregnancy and lactation:Recommendations for FDA - Category X. The drug is not recommended for use in women. Because the finasteride inhibits the conversion of testosterone to dihydrotestosteroneit, its use during pregnancy can cause violations of the formation of external genital organs in male fetuses. Absorbed from the surface of intact skin. Pregnant women and women of reproductive age should not touch broken or destroyed tablets of finasteride (undamaged finasteride tablets are covered with a special coating, which prevents contact with the active ingredient).
Dosing and Administration:Inside, 5 mg once a day for 6-7 months. The first evaluation of effectiveness is carried out after 6 months.
Side effects:Decreased potency and / or libido, impaired ejaculation, decreased ejaculate volume, increased and soreness of mammary glands, increased levels of LH and FSH in blood, decreased concentration of prostate-specificantigen, allergic reactions (rash, itching, urticaria, swelling of the lips and face).
Interaction:The feather-grass of the perforated herb extract reduces the effectiveness of finasteride.
Special instructions:With a large volume of residual urine and a reduced current, one should keep in mind the possibility of developing obstructive uropathy. Before the start of treatment, prostate cancer and infectious prostatitis should be excluded.
It should be borne in mind that finasteride penetrates into the seminal fluid.
Impact on the ability to drive vehicles and manage mechanisms.
The adverse effects of the drug on the ability to engage in potentially hazardous activities requiring increased attention and rapid psychomotor reactions were not reported.